Russian Journal of Infection and ImmunityRussian Journal of Infection and ImmunityИнфекция и иммунитет2220-76192313-7398SPb RAACI1756410.15789/2220-7619-ATA-17564ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleAntibody titer after anti-idiotype rabies vaccination with nano-chitosan adjuvantОценка титра антител после антиидиотипной вакцинации против бешенства с адъювантом нанохитозаномParyatiSayu Putu YuniПарьятиСаю Путу Юни
Indonesia

Doctor of Veterinary Medicine, Lecturer at the Faculty of Medicine

доктор ветеринарной медицины, преподаватель медицинского факультета

yunisayu@yahoo.comRamadhantiS.РамадхантиШ.
Indonesia

Doctor of Medicine, Graduate of the Faculty of Medicine

доктор медицины, выпускник медицинского факультета

yunisayu@yahoo.comHasanK.ХасанХ.
Indonesia

PhD of Protein Engineering, Lecturer at the Department of Biochemistry, Faculty of Medicine

PhD по белковой инженерии, преподаватель кафедры биохимии медицинского факультета

yunisayu@yahoo.comGeneral Achmad Yani UniversityУниверситет генерала Ахмада Яни06082024311020241447887940301202416052024Copyright ©; 2024, Paryati S.P., Ramadhanti S., Hasan K.Copyright ©; 2024, Парьяти С.П., Рамадханти Ш., Хасан Х.2024Paryati S.P., Ramadhanti S., Hasan K.Парьяти С.П., Рамадханти Ш., Хасан Х.https://creativecommons.org/licenses/by/4.0https://iimmun.ru/iimm/article/view/17564

Background. The rabies virus neutralizing antibodies titers is a public health problem in the world, including Indonesia. Rabies is zoonotic and causes death in humans with a case fatality rate of 100%. Anti-idiotype antibody (Ab2) from chicken immunoglobulin (IgY) can be a substitute antigen for the rabies virus. This research aims to study the potential of rabies vaccine based on anti-idiotype antibody (Ab2) with nano-chitosan as an adjuvant. Materials and methods. The production of Ab2 is derived from purified and characterized chicken immunoglobulins. Nano-chitosan is made from chitosan from shrimp shell waste. Vaccination tests were carried out on rats compared with commercial vaccines as a positive control and physiological solutions as a negative control. The characterization results of IgY Ab2 were IgY rabies with BM ~180 kDa, heavy chains (BM ~60 kDa), and light chains (BM ~30 kDa) of IgY. Nano-chitosan is less than 100 nm in size, can dissolve well, and does not cause side effects in experimental animals. Results. The vaccine formula uses a concentration of 0.5%, where the ratio of nano-chitosan and Ab2 is 1:1. The Ab2 concentration used was about 1000 units per mL of the Ab2 suspension. Conclusion. This study concludes that anti-idiotype antibodies dissolved in nano-chitosan adjuvant can induce the formation of antibodies with titers that are not statistically different from the antibody titers induced by commercial rabies vaccines. Nano-chitosan has a potential vaccine adjuvant candidate, safe to use, and can enhance the immunogenicity of an antigen applied subcutaneously. According to the results of this study, it is recommended that post-vaccination antibody titers be measured regularly: for example, every one week for six weeks after vaccination. This measurement determines the time of the peak of the antibody titer so that the time for revaccination can be determined.

Введение. Бешенство — зоонозная инфекция с летальностью 100%. Антиидиотипические антитела (Ab2) из куриного иммуноглобулина (IgY) могут использоваться в качестве замещающего антигена вируса бешенства. Целью настоящего исследования было изучение потенциала вакцины против бешенства на основе антиидиотипических антител (Ab2) с нанохитозаном в качестве адъюванта, с оценкой уровня титра антител, нейтрализующих вирус бешенства. Материалы и методы. Ab2 получают из очищенных куриных иммуноглобулинов. Нанохитозан производится из хитозана панциря креветок. Оценка вакцинации проводилась на крысах в сравнении с коммерческими вакцинами в качестве положительного контроля и физиологическим раствором в качестве отрицательного контроля. Характеристики использованной вакцины: IgY Ab2 IgY против антигена бешенства с Mr ~180 kDa, тяжелые цепи (Mr ~60 kDa) и легкие цепи (Mr ~30 kDa) IgY. Нанохитозан имеет размер менее 100 нм, хорошо растворяется и не вызывает побочных эффектов у экспериментальных животных. Результаты. Вакцина используется в концентрации 0,5%, где соотношение нанохитозана и Ab2 составляет 1:1, при концентрации Ab2 около 1000 единиц на мл суспензии Ab2. Выводы. Настоящее исследование позволяет заключить, что антиидиотипические антитела, растворенные в адъюванте нанохитозана, могут вызывать образование антител с титрами, которые статистически не отличаются от таковых, индуцированных коммерческими вакцинами против бешенства. Нанохитозан является потенциальным кандидатом в качестве адъюванта вакцины, безопасен в использовании и может усиливать иммуногенность антигена при подкожном введении. Согласно результатам данного исследования, титры антител после вакцинации рекомендуется измерять регулярно: например, каждую неделю в течение шести недель после вакцинации, что позволяет определить время пика титра антител для установления времени ревакцинации.

anti-idiotypeantibodychicken immunoglobulinschitosanrabiesvaccineантиидиотипантителокуриные иммуноглобулиныхитозанбешенствовакцинаAbbas A.K., Lichtman A.H., Pillai S. Basic immunology: functions and disorders of the immune system. St. Louis, Missouri: Elsevier Science Pub Co, 2016. URL: https://archive.org/details/basicimmunologyf0000abba_w9e9American Veterinary Medical Association. AVMA Guidelines for the Euthanasia of Animals. 2013. URL: https://www.avma.org/resources-tools/avma-policies/avma-guidelines-euthanasia-animalsAmri Y., Fajri R., Novitasari P., Zulfajri M. The effect of tripolyphosphate (tpp) volumes on the synthesis of chitosan nanoparticles using ionic gelation method. Proceedings of the 2nd International Conference on Science, Technology, and Modern Society (ICSTMS 2020), 2021, vol. 576, pp. 213–216. doi: 10.2991/assehr.k.210909.048National Research Council. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC: The National Academies Press, 2011. doi: 10.17226/12910Data and Information Center of the Ministry of Health of the Republic of Indonesia. Rabies situation and analysis in 2014. Jakarta: Ministry of Health of the Republic of Indonesia, 2014. URL: https://p2pm.kemkes.go.id/storage/publikasi/media/file_1619049298.pdfDe Jong J.C., Palache A.M., Beyer W.E.P., Rimmelzwaan G.F., Boon A.C.M., Osterhaus A.D.M.E. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. (Basel), 2003, vol. 115, pp. 63–73.Doan C.T., Tran T.N., Nguyen V.B., Nguyen A.D., Wang S.-L. Production of a thermostable chitosanase from shrimp heads via Paenibacillus mucilaginosus TKU032 conversion and its application in the preparation of bioactive chitosan oligosaccharides chien. Mar. Drugs, 2019, vol. 17, no. 4: 217. doi: 10.3390/md17040217Dzung N.A. Chitosan and chitosan derivatives as potential adjuvants for influenza vaccine. In: Chitin and chitosan derivatives: Advances in drug discovery and developments. Ed. Kim S.K. Boca Raton: CRC Taylors & Francis, 2014, pp. 481–492. doi: 10.1201/b15636European Commission: Directorate-General for Environment. Caring for animals aiming for better science — Directive 2010/63/EU on protection of animals used for scientific purposes: Animal welfare bodies and national committees, 2018. URL: https://data.europa.eu/doi/10.2779/059998Fisher C.R., Schnell M.J. New developments in rabies vaccination. Rev. Sci. Tech., 2018, vol. 37, no. 2, pp. 657–672. doi: 10.20506/rst.37.2.2831Holley T., Bowe G., Campia I., Belz S., Berggren E., Janusch Roi A., Wittwehr C., Whelan M. European Union Reference Laboratory for Alternatives to Animal Testing: Dataset Collection, 2017. URL: https://joint-research-centre.ec.europa.eu/eu-reference-laboratory-alternatives-animal-testing-eurl-ecvam_enHunter R.L. Overview of vaccine adjuvants: present and future. Vaccine, 2002, vol. 20, no. 3, pp. 7–12. doi: 10.1016/s0264-410x(02)00164-0Li X., Dong W., Nalin A.P., Wang Y., Pan P., Xu B. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells. Oncoimmunology, 2018, vol. 7, no. 6: e1431085. doi: 10.1080/2162402X.2018.1431085Mursal I.L.P., Warsito A.M.P., Ariyanti D.K., Susanti E., Irma R. Use of chitosan nanoparticles as new drug delivery. Journal of Pharmaceutical and Sciences, 2023, vol. 6, no. 2, pp. 804–809. doi: 10.36490/journal-jps.com.v6i2.136Paryati S.P.Y., Hasan K., Nawangsih E.N., Inayati I., Rakhmat. Purification and characterization of rabies anti-idiotype antibodies isolated purification and characterization of rabies anti-idiotype antibodies isolated from chicken egg yolks. Int. J. Pharm. Res., 2020, vol. 12, no. 3, pp. 1629–1634. doi: 10.31838/ijpr/2020.12.03.223Paryati S.P.Y., Nawangsih E.N., Inayati I., Rakhmat. Preparation of anti-idiotype antibody as diagnostic kit in rabies serological test. 4th Syiah Kuala University Annual International Conference 2014; Banda Aceh, Indonesia, 2014, pp. 138–143. URL: https://www.neliti.com/publications/174146/preparation-of-anti-idiotype-antibody-as-diagnostic-kit-in-rabies-serological-teParyati S.P.Y., Wibawan I.W.T., Soejoedono R.D., Pasaribu F.H. Chicken immunoglobulin as an anti-idiotype antibody against rabies (Imunoglobulin ayam sebagai antibodi anti-idiotipe terhadap rabies). J. Vet., 2006, vol. 7, no. 3, pp. 92–103.Pasquale A.D., Preiss S., Silva F.T.D., Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel), 2015, vol. 3, no. 2, pp. 320–343. doi: 10.3390/vaccines3020320Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol., 2004, vol. 82, no. 5, pp. 488–496. doi: 10.1111/j.0818-9641.2004.01272.xRoitt I.M., Brostoff J., Male D.K. Immunology 3rd ed. London: Mosby-Year Book Europe Ltd. 2003. URL: https://books.google.co.id/books/about/Immunology.html?id=a6tpAAAAMAAJ&redir_esc=yRoitt I.M., Delves P.J. Roitt‘s essential immunology. UK: Blackwell Science Ltd. 2001. URL: https://dl.mehrsys.ir/pdf-books/Roitt_s%20Essential%20Immunology%20Thirteenth%20Edition(www.myuptodate.com).pdfSaha A., Chatterjee S.K., Foon K.A., Primus F.J., Sreedharan S., Mohanty K. Dendritic cells pulsed with an anti-idiotype antibody mimicking Carcinoembryonic Antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res., 2004, vol. 64, no. 14, pp. 4995–5003. doi: 10.1158/0008-5472.CAN-04-0626Toovey S. Preventing rabies with the Verorab vaccine: 1985–2005 Twenty years of clinical experience. Travel Med. Infect. Dis., 2007, vol. 5, no. 6, pp. 327–348. doi: 10.1016/j.tmaid.2007.07.004.WHO. Rabies vaccines. 2002. URL: https://www.who.int/publications/i/item/who-wer7714WHO. Rabies. 2024. URL: https://www.who.int/news-room/fact-sheets/detail/rabiesWHO. Rabies outbreak response: Accelerating a One Health approach in East NusaTenggara. 2023. URL: https://www.who.int/indonesia/news/detail/18-10-2023-rabies-outbreak-response--accelerating-a-one-health-approach-in-east-nusa-tenggaraZhou E.M., Fischer M.M.D., Rector E.S., Sehon A.H., Kisil F.T. A murine monoclonal anti-idiotypic antibody detects a common idiotope on human, mouse and rabbit antibodies to allergen lol p IV. Scand. J. Immunol., 1991, vol. 34, pp. 307–316. doi: 10.1111/j.1365–3083.1991.tb01551.x